Lantus Compassionate Use and Expanded Access

Why "Compassionate Use" Does Not Apply to Lantus

Formal compassionate use, known in FDA regulatory language as expanded access, exists for drugs that are not yet approved or not commercially available. Lantus received FDA approval in April 2000 and has been continuously marketed since then. FDA regulations at 21 CFR Part 312 Subpart I define expanded access as a pathway for patients with serious conditions to use investigational drugs outside a clinical trial. Because Lantus is approved and on pharmacy shelves, the FDA expanded access framework does not apply to it.

What "Access" Actually Means for Lantus Patients

The access problem for Lantus is financial, not regulatory. The American Diabetes Association's 2024 Standards of Care note that "cost and access barriers to optimal diabetes management remain significant in the United States, with insulin affordability cited as a primary driver of cost-related underuse" (ADA Standards of Care 2024). One study in JAMA Internal Medicine found that 25% of insulin-dependent patients reported rationing insulin doses because of cost (Herkert et al., JAMA Internal Medicine 2019). Dose rationing raises hemoglobin A1c and increases hospitalization risk. That is the real access crisis.

FDA Expanded Access: When It Would Apply

If a patient needed an investigational insulin analog not yet approved, they could submit an individual patient expanded access request through FDA's expanded access portal. Sponsoring physicians file FDA Form 3926. Approval typically comes within days for immediately life-threatening situations. For Lantus specifically, no such filing is needed or appropriate.

Sanofi's Insulins Valyou Savings Program

Sanofi operates the most direct financial assistance route for Lantus. The Insulins Valyou Savings Program offers eligible commercially insured patients a copay card capping out-of-pocket costs at $99 per month for all Sanofi insulins combined, regardless of the number of prescriptions. Patients without commercial insurance can apply for the Patient Assistance Program (PAP) track, which provides free insulin to those below roughly 400% of the federal poverty level.

How to Apply

Applications are submitted at Sanofi's Insulins Valyou portal or by calling 1-888-847-4877. Required documents typically include proof of income (recent tax return or pay stub), a valid prescription, and insurance information (or denial letter). Most PAP approvals take 3 to 10 business days. Emergency bridge supplies of 30-day insulin are sometimes available within 72 hours when a provider certifies urgent need.

Income Thresholds and Supply Quantities

The PAP track covers one 10 mL vial or one box of five KwikPens per 30-day cycle, with renewals every 90 days. Patients living at or below 200% of the federal poverty level generally receive a full free supply. Those between 200% and 400% may receive partial assistance or the $99/month copay cap. Sanofi updates income thresholds annually; the most current figures appear on the Sanofi Patient Connection page.

Bridge Insulin While Awaiting Approval

Gap periods between PAP approval cycles are common. Several options cover this window. Walmart sells ReliOn brand NPH and regular human insulin over the counter for $25 per vial in most states, though these are not insulin analogs and require different dosing adjustments that a prescribing clinician must guide. The ADA's insulin access resource page notes that human insulin remains "an effective option for many patients with type 2 diabetes when analog insulins are not affordable" (ADA 2024 Standards of Care, Section 9).

FDA-Interchangeable Biosimilars: The Fastest Cost Reduction

Three FDA-approved interchangeable biosimilars of insulin glargine are on the U.S. Market as of 2026. Interchangeable status means a pharmacist can substitute them for Lantus without a new physician authorization in most states, the same way generic drugs are substituted.

Semglee (insulin glargine-yfgn)

Semglee, manufactured by Viatris, was designated the first interchangeable insulin biosimilar by the FDA in July 2021 (FDA approval letter, Semglee). Its list price is approximately 65% of Lantus's list price. A GoodRx coupon for Semglee at major pharmacy chains frequently brings the cash price to $80, $120 per vial, compared to $290, $340 for Lantus. Clinically, the pharmacokinetic profile of Semglee is equivalent to Lantus, with a flat peakless action duration of approximately 24 hours (FDA biosimilar product information).

Basaglar (insulin glargine-aabc)

Basaglar, from Eli Lilly, was approved by the FDA in December 2015 as a "follow-on" biological product and received full interchangeable status in 2022. Lilly's Insulin Value Program caps Basaglar at $35 per month for eligible patients through insulinaffordability.com. This program has no income requirement.

Rezvoglar (insulin glargine-aglr)

Rezvoglar, also from Eli Lilly, launched in January 2023 at a list price of $92 per vial, roughly one-third of Lantus's list price (FDA label, Rezvoglar). Lilly's $35/month cap also covers Rezvoglar.

Clinical Equivalence Data

A 2020 Cochrane review of insulin glargine biosimilars (including the compound in Semglee) found no statistically significant difference in HbA1c reduction, hypoglycemia rates, or immunogenicity between biosimilars and the reference product across 19 randomized controlled trials (Cochrane Database of Systematic Reviews, biosimilar insulins). Switching patients from Lantus to an interchangeable biosimilar does not require re-titration in most cases, though blood glucose monitoring for the first two weeks after any insulin switch is standard practice.

340B Drug Pricing Program

Federally Qualified Health Centers (FQHCs), community health centers, and certain hospitals participating in the 340B Drug Pricing Program can purchase Lantus at significantly reduced prices and pass those savings to patients. Under 340B, covered entities buy outpatient drugs at or below the ceiling price set by the Health Resources and Services Administration (HRSA), which runs roughly 20% to 50% below wholesale acquisition cost for brand insulins.

Finding a 340B Pharmacy

The HRSA maintains a searchable database of 340B-covered entities at hrsa.gov/opa/eligibility-and-registration/covered-entities. Patients do not need insurance to use a 340B pharmacy. They do need to be a patient of the covered entity, meaning at least one visit or established care at that health center. Many FQHCs use a sliding-fee scale for the clinical visit itself, so total out-of-pocket for insulin plus visit can remain under $75 for uninsured patients living below 200% of the federal poverty level.

Insulin Prices at 340B Sites

A 2023 JAMA Health Forum analysis found that patients at 340B hospitals paid a mean of $38 per insulin vial compared to $275 at non-340B retail pharmacies (JAMA Health Forum, 340B insulin pricing analysis). The difference is substantial and often overlooked by patients and providers alike.

State Insulin Cost-Cap Laws

Twenty-four states have enacted insulin copay cap legislation as of early 2026, with caps ranging from $25 per 30-day supply in Maine, Colorado, and New Mexico to $100 per 30-day supply in several other states. These caps apply to insured patients only. Uninsured patients must use manufacturer programs or 340B sites.

Checking Your State's Law

The National Academy for State Health Policy maintains a tracker at nashp.org/state-actions-to-address-insulin-costs. A patient whose state has a $35 cap on insulin copays does not need to apply for any separate assistance program. They simply present their prescription and insurance card at the pharmacy, and the pharmacist applies the cap automatically.

Federal Inflation Reduction Act (IRA) Provisions

Under the Inflation Reduction Act of 2022, Medicare Part D insulin copays are capped at $35 per month per insulin beginning January 2023 (CMS IRA insulin cap fact sheet). This applies to all Medicare beneficiaries with Part D coverage. Medicare Advantage plans with Part D drug benefits must comply with the same cap. This federal cap does not extend to commercial insurance plans, though the Consolidated Appropriations Act of 2023 encouraged but did not require commercial payers to adopt similar caps.

Prescription Discount Cards and Pharmacy Programs

Prescription discount cards are not insurance but function as negotiated pricing agreements between pharmacy benefit networks and pharmacies. GoodRx, RxSaver, NeedyMeds, and CostPlus Drugs (Mark Cuban's pharmacy) all list prices for insulin glargine biosimilars that are meaningfully lower than cash retail prices.

Mark Cuban's Cost Plus Drugs

Cost Plus Drugs at costplusdrugs.com lists Semglee (insulin glargine-yfgn) at a transparent markup of cost plus 15% plus a $3 pharmacy fee. As of late 2025, that price was approximately $88 per vial. No membership or insurance is required. Prescriptions are mailed to patients.

GoodRx Pricing for Biosimilars

GoodRx consistently lists Semglee and Basaglar at $75 to $130 per vial depending on pharmacy and region. Lantus itself, by contrast, rarely falls below $250 via GoodRx coupons because Sanofi's wholesale pricing structure limits third-party discount depth on the branded product. The practical implication: patients who insist on branded Lantus rather than an interchangeable biosimilar will pay two to three times more at the pharmacy counter.

HSA and FSA Coverage for Lantus

Lantus and all FDA-approved insulin analogs are qualified medical expenses under IRS Publication 502, meaning they are fully eligible for payment with Health Savings Account (HSA) or Flexible Spending Account (FSA) funds (IRS Publication 502, Medical and Dental Expenses). This includes the cost of insulin, syringes, pen needles, and continuous glucose monitors used alongside Lantus.

How HSA/FSA Changes the Effective Price

An HSA contribution is made with pre-tax dollars. A patient in the 22% federal tax bracket who pays $300 for a Lantus vial from their HSA effectively pays $234 in after-tax dollars. Combined with a biosimilar switch to Semglee and an HSA, the effective after-tax cost can drop to $60 to $90 per vial. Patients with high-deductible health plans should confirm HSA eligibility with their plan administrator, as IRS rules require a qualifying HDHP for HSA contributions.

FSA Deadlines and Grace Periods

FSA funds are typically "use it or lose it" by December 31 unless the plan offers a grace period or $660 rollover (2025 IRS limit). Insulin is a predictable recurring expense, making it an appropriate target for FSA planning. A patient using one vial of insulin glargine per month can estimate annual insulin costs precisely and elect FSA contributions accordingly.

When a Prescribing Clinician Can Help

Access problems often have clinical solutions that do not involve assistance programs at all. A prescribing physician or advanced practice provider can:

• Switch the patient to an interchangeable biosimilar with a single prescription change.
• Write the prescription as "insulin glargine, substitution permitted" so the pharmacist can dispense the lowest-cost interchangeable product available that day.
• Prescribe Lantus SoloStar pens as a vial-plus-syringe prescription instead, which sometimes results in different tier placement on formulary.
• Document medical necessity for a formulary exception if a plan's preferred tier covers Basaglar but not Lantus and the patient has a documented reason to remain on Lantus specifically.

The Endocrine Society's 2023 Clinical Practice Guideline on insulin therapy states that "clinicians should prescribe the lowest-cost insulin that safely achieves glycemic targets for each patient, and should proactively review cost at every prescription renewal" (Endocrine Society, Insulin Therapy CPG 2023). That recommendation places the cost conversation squarely in the clinical encounter rather than leaving patients to manage it alone.

Dose Optimization to Reduce Vial Consumption

Some patients use more insulin than needed due to suboptimal titration, chronic hyperinsulinemia from dietary factors, or resistance from unmanaged weight. Structured basal insulin titration protocols, such as the treat-to-target titration used in the EDITION trials, achieved fasting glucose of 80 to 100 mg/dL in most patients with type 2 diabetes using mean daily doses of 0.4 to 0.6 units/kg with Lantus (EDITION 2 trial, N=811, Lancet 2014). Optimized titration reduces total vial consumption per month, directly lowering cost.

Combining Programs: A Decision Framework

Patients often qualify for more than one discount mechanism simultaneously. The following hierarchy reflects 2026 program availability and typical savings depth:

1. Medicare Part D beneficiaries: Use the $35/month IRA cap first. No other program needed in most cases.
2. Commercially insured with state copay cap: Use the state cap. Confirm with pharmacist.
3. Commercially insured without state cap: Apply for Sanofi Valyou copay card ($99/month max) or switch to biosimilar plus Lilly's $35/month program.
4. Uninsured, income below 400% FPL: Apply for Sanofi PAP (free insulin) and establish care at a 340B FQHC as backup.
5. Uninsured, income above 400% FPL: Switch to biosimilar, use Cost Plus Drugs or GoodRx pricing, pay with HSA/FSA pre-tax dollars.
6. Any patient: Ask prescriber to write "substitution permitted" on all insulin prescriptions.

A 2022 Health Affairs analysis found that patients who combined a manufacturer copay card with a pharmacy discount network paid a mean of $48 per insulin fill, compared to $112 for those using only one mechanism (Health Affairs, insulin out-of-pocket costs 2022). Stacking legally permitted programs is not fraud; it is informed consumerism.

Traveling Internationally for Insulin

Some U.S. Patients purchase insulin glargine abroad. In Canada, insulin glargine is sold under the Lantus brand by Sanofi at roughly CAD $50 to $80 per vial (approximately USD $37 to $60). In Mexico, it is available without a prescription at many pharmacies for USD $25 to $45 per vial. The FDA technically prohibits personal importation of prescription drugs, but FDA enforcement policy states that it generally exercises enforcement discretion for personal-use quantities (a 90-day supply) of drugs that pose no safety concern and are for a serious condition. Insulin clearly meets that standard. Patients should carry original packaging and a copy of their U.S. Prescription when crossing borders.

Cold-chain integrity is the primary safety concern. Insulin glargine should remain at 36 to 46 degrees Fahrenheit until opened and at room temperature (below 77 degrees Fahrenheit) for no more than 28 days after opening, per the Lantus prescribing information. Airport security and long bus rides in warm climates create genuine cold-chain risk that patients must plan for with a portable insulin cooler.

Documentation Checklist for Assistance Applications

Gathering documents before starting any application reduces processing time. The following list covers requirements common to Sanofi PAP, 340B enrollment, and state low-income health program applications:

• Current valid prescription for insulin glargine (dated within 6 months)
• Most recent federal tax return (Form 1040) or two recent pay stubs
• Photo ID (driver's license, passport, or state ID)
• Insurance card or denial letter from insurer
• Completed manufacturer application form (downloadable from Sanofi Patient Connection)
• Physician's office contact information for program verification calls

Applications submitted with all documents at once are processed faster. Sanofi's PAP team requests the prescribing physician's DEA number and NPI in some cases, so alerting the prescribing office before submission helps.